Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Active Psoriatic Arthritis (Phase 3, 24-week Double-Blind with Long-Term Extension)
2016-004675-52Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in psoriatic arthritis (PsA), sponsored by Eli Lilly and Company. Started Mar 2017; status: active.
02
Drugs
baricitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2016-004675-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004675-52.